The actor’s luxury rebrand just collided with a very different kind of skincare company.
Brad Pitt is back in court, but this time it has nothing to do with his ex-wife or a French winery. A Malibu-based company specializing in intimate skincare products for men has filed a federal lawsuit against the actor’s luxury beauty line, Beau Domaine.
The plaintiff, a brand called Beau D., claims that Pitt’s decision to rebrand his skincare venture last year created an unfair market advantage. The company launched in 2020 with a unique product lineup. The legal complaint alleges false designation of origin and unfair competition, seeking a permanent injunction and damages exceeding $75,000.
The core of the dispute is relatively simple: names. Pitt originally launched his unisex skincare line in 2022 as Le Domaine in partnership with a famous French winemaking family. However, in a major rebranding effort last year, the actor changed the label to Beau Domaine.
According to court documents, the smaller brand argues that the similarity between “Beau D.” and “Beau Domaine” is likely to confuse customers. The founder attempted to settle the matter privately three times before resorting to litigation. The proposed options included a full rebrand by Pitt’s side, financial compensation, or funding for the smaller company to change its own name.
While the legal arguments focus on trademark law, the specific product line of the plaintiff has drawn significant attention. Beau D. markets a specific cream for male genitalia, described by its creator as a formula designed to boost collagen production and slow the aging process of the skin.
The company’s marketing is intentionally provocative. The product aims to put confidence back into the customer’s hands, utilizing a blend of high-end ingredients typically found in facial serums.
So far, representatives for Brad Pitt and the Beau Domaine brand have remained silent on the allegations. The company has not yet filed a formal legal response to the complaint.
This legal wrangling comes as the actor continues to navigate a separate, high-stakes battle over the sale of his stake in Château Miraval. The court will now have to determine whether the shared prefix “Beau” is enough to constitute trademark infringement or if two very different skincare companies can coexist.
